Other substances

Fimasartan

An angiotensin II receptor antagonist.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Fimasartan on PubChem

Marketed as

KANARB

 

Structure image - Fimasartan

CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease
3CLpro Small molecule In vitro In silico 		in silico; Vero E6 cells

Showed low free energy in a molecular docking in silico analysis with SARS-CoV-2 3C-like protease (high affinity) and sufficient stability within molecular dynamics simulation of the interaction.

 Dec/03/2020
Export (.csv)